Interview with: Nicholas Landekic, Co-Founder, President and CEO - featuring: their biomimetics - novel small molecule drugs which mimic the activity of proteins, with products in two therapeutic areas: infectious diseases, with novel antibiotic drugs which mimic the activity of the host defense proteins; and acute cardiovascular, with a new heparin antagonist. |
|
| PolyMedix, Inc.
(PYMX-OTC: BB) |
|
|
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
This is a printer friendly page! PolyMedix uses a proprietary computational drug design technology
to create small molecules that mimic the activity of proteins and apply this technology to
membrane protein and protein-protein targets, with a commercial focus of serious, life
threatening acute disorders, which are also major market opportunities
|
|
“What we try to do at PolyMedix is innovation, but with risk mitigation. We are focused on developing innovative products; small molecules that mimic the activity of protein as a disruptive business model, this is a big deal. We have shown that we can successfully create products with our technology, and hope to have two compounds entering clinical development this year. The therapeutic areas we have chosen to work in have been rationally and strategically selected; acute cardiovascular and infectious diseases are both characterized as having relatively fast, inexpensive and straightforward clinical trials, and are both areas where Phase I human trials, the first human testing, is often considered clinical proof of principle. However, these are also blockbuster market opportunities. At the same time we are developing drugs, we are also trying to mitigate risk by developing antimicrobial polymers for materials uses. Our scientific founders from The University of Pennsylvania are world renowned, members of the National Academy of Sciences, and universally regarded as the world leaders in biochemistry and biophysics. Most importantly, we have a highly experienced management team in place at PolyMedix - all of us have turned science into profits many times before, and we plan to do it again at PolyMedix.” - Nicholas Landekic |
|
